KAKEN PHARMACEUTICAL CO.,LTD.(4521) News

KAKEN PHARMA, Returning to Profitability This Year

[Summary] Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 [JGAAP]

Updates on Actions to Implement Management that is Conscious of Cost of Capital and Stock Price

Notice Regarding Differences Between Non-Consolidated Financial Results and Results for the Previous Fiscal Year

Revision of FY2026 Earnings Forecast and J&J Milestone Revenue

KAKEN PHARMA, Ordinary Profit Forecast for Last Fiscal Year Revised Downward to a Loss

Announcement on Changes of the Board of Directors and Corporate Officers

KAKEN PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 96%, Oct-Dec Ordinary Profit Decreases by 91%

[Summary]Consolidated Financial Results for the Nine Months Period of Fiscal 2025 (Nine Month Period Ended December 31, 2025) [JGAAP]

Announcement of the Result of Phase III Clinical Trial of KP-001 in Japan

[Summary] Consolidated Financial Results for the Six-Months Period of Fiscal 2025 (Six-Month Period Ended September 30, 2025) [JGAAP]

KAKEN PHARMA, First Half Ordinary Profit Decreases by 97%, Jul-Sep Ordinary Profit Decreases by 99%

Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026

KAKEN PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 53%

Approval for Marketing Authorization for Efinaconazole in Germany for the Treatment of Onychomycosis

Approval for Marketing Authorization for ECCLOCK gel 5% in Korea for Treatment of Primary Axillary Hyperhidrosis

Strategic Collaboration with Astria Therapeutics, Inc. to Develop and Commercialize Navenibart for Hereditary Angioedema in Japan

[Summary] Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025) [JGAAP]

KAKEN PHARMA, Apr-Jun (1Q) Ordinary Profit Decreases by 86%

License Agreement for “gMSC1”, the Allogenic Synovial Mesenchymal Stem Cell-Derived Three-Dimensional Artificial Tissue